| Stereochemistry | ABSOLUTE |
| Molecular Formula | C31H27BrO3S |
| Molecular Weight | 559.513 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(C)C2=C(S1)C(Br)=C3C=CC=CC3=C2C4=CC(C)=C(O[C@H](CC5=CC=CC=C5)C(O)=O)C(C)=C4
InChI
InChIKey=FONCZICQWCUXEB-RUZDIDTESA-N
InChI=1S/C31H27BrO3S/c1-17-14-22(15-18(2)29(17)35-25(31(33)34)16-21-10-6-5-7-11-21)27-23-12-8-9-13-24(23)28(32)30-26(27)19(3)20(4)36-30/h5-15,25H,16H2,1-4H3,(H,33,34)/t25-/m1/s1
Ertiprotafib was originally developed as an inhibitor of PTP1B. Multiple targets of ertiprotafib, in addition to PTP1B inhibition, have been suggested including dual PPARalpha/PPARgamma agonism and IKK-beta inhibition. It normalized the plasma glucose and insulin levels in diabetic animal models and progressed to a phase II clinical trial for the treatment of Type 2 diabetes mellitus. Ertiprotafib development has been discontinued.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 0.87 µM [IC50] | |||
| 400.0 nM [IC50] |
PubMed
ACTIVE MOIETY
